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Abstract: Estrogen receptors (ER) are known to play an important regulatory role in mammary gland development 
as well as in its neoplastic transformation. Although several studies highlighted the contribution of ER signaling in 
the breast transformation, little is known about the dynamics of ER state of activity during carcinogenesis due to 
the lack of appropriate models for measuring the extent of receptor signaling in time, in the same animal. To this 
aim, we have developed a reporter mouse model for the non-invasive in vivo imaging of ER activity: the ERE-Luc 
reporter mouse. ERE-Luc is a transgenic mouse generated with a firefly luciferase (Luc) reporter gene driven by a 
minimal promoter containing an estrogen responsive element (ERE). This model allows to measure receptor signal-
ing in longitudinal studies by bioluminescence imaging (BLI). Here, we have induced sporadic mammary cancers 
by treating systemically ERE-Luc reporter mice with DMBA (9,10-dimethyl 1,2-benzanthracene) and measured re-
ceptor signaling by in vivo imaging in individual animals from early stage until a clinically palpable tumor appeared 
in the mouse breast. We showed that DMBA administration induces an increase of bioluminescence in the whole 
abdominal area 6 h after treatment, the signal rapidly disappears. Several weeks later, strong bioluminescence is 
observed in the area corresponding to the mammary glands. In vivo and ex vivo imaging analysis demonstrated that 
this bioluminescent signal is localized in the breast area undergoing neoplastic transformation. We conclude that 
this non-invasive assay is a novel relevant tool to identify the activation of the ER signaling prior the morphological 
detection of the neoplastic transformation. 
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Introduction
The ER signaling plays a pivotal role during the 
normal, hyperplastic, dysplastic and neoplastic 
growth and differentiation of the breast tissue 
[1]. Receptor activation influences the genetic 
program of the cell via direct modulation of tar-
get genes in the nucleus or by interfering with 
the signaling of other molecules in the cyto-
plasm or within the plasmalemma [2]. Modula- 
tion of receptor activity may occur through sev-
eral mechanisms, including alterations of the 
ER expression levels [3], changes in the ovarian 
or local production of estrogens [4], post-trans-
lational modifications (including phosphoryla-
tions, sumoylations, palmytoilations and acety-
lations) known to influence the receptor signal-
ing [5]. Due to its importance in mammary 
gland homeostasis, ER serves as a therapeutic 
target and as a predictive marker of sex hor-
mone sensitivity and is a key factor in the devel-
opment of hormone responsive breast cancers 
[6]. 
In the last three decades in vitro and in vivo 
methodologies were applied to elucidate the 
precise role of ER in hormone-dependent carci-
nogenesis and advanced in silico technologies 
such as genomics and proteomics character-
ized the downstream effectors of estrogen sig-
naling in breast carcinogenesis [7-11]. The stat-
ic nature of these methodologies, however, lim-
its the power of the analysis providing a snap-
shot of specific phase of tumorigenesis, but not 
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the dynamic view of the receptor modulation 
necessary to identify the specific steps where 
the receptor signaling is indispensible for tumor 
progression [12]. 
To overcome these limitations, we developed 
the reporter mouse technology and applied in 
vivo imaging methodologies suitable to mea-
sure the activity of molecular targets in physio-
logical settings [13]. In previous studies, we 
have extensively validated the ERE-Luc reporter 
mouse, a transgenic mouse carrying a firefly 
luciferase reporter system ubiquitously respon-
sive to ER signaling and expressing the reporter 
proportionally to the state of ER activation [14]. 
This mouse model has represented a novel, 
promising, approach to follow in time the 
dynamics of ER activation in physiology [15] 
and was hypothesized to provide novel insights 
on the temporal regulation of ER signaling dur-
ing tumorigenesis [12]. 
In this study, we induced a breast carcinoma in 
the ERE-Luc mouse model with the application 
of a classical protocol of chemical carcinogen-
esis based on the systemic treatment with 
DMBA [16]. Taken together our results demon-
strated the possibility to monitor ER signaling 
during the breast cancer progression to identify 
the stages at which the receptor signaling 




DMBA was purchased from Sigma-Aldrich 
(Pomezia, Italy), ketamine (Imalgene 500) from 
Merial (Toulouse France), xilazine (Rompun) 
from Bayer (Shawnee Mission, Kansas, USA), 
and D-luciferin (Beetle luciferin potassium salt) 
from Promega (Milan, Italy).
Experimental animals and rodent diets
The ERE-Luc mouse model is a transgenic 
mouse generated to measure the ER activity in 
the mouse tissue; the procedure for the gener-
ation of the model and its validation has been 
previously described [14]. Briefly, the construct 
used for transgenesis consisted of the reporter 
gene (firefly luciferase) driven by a dimerized 
ERE and a minimal promoter. Insulator sequenc-
es, the matrix attachment region from chicken 
lysozyme, were use to flank the reporter system 
in the transgenesis construct to achieve a gen-
eralized, hormone-responsive reporter expres-
sion. In this transgenic reporter mouse we have 
showed by biochemical, immunohistochemical, 
and pharmacological criteria, that luciferase 
content reflects ER transcriptional activity and 
thus represents a novel system for the study of 
the ER dynamics during physiological fluctua-
tions of estrogen and for the identification of 
SERMs or endocrine disruptors [14]. 
The current study was carried out using hetero-
zygous 8 weeks old mature female ERE-Luc 
mice in the C57BL/6 genetic background. 
Animal colonies were housed according to the 
Guidelines for Care and Use of Experimental 
Animals. All animal studies were approved by 
the Italian Ministry of Research (DM124/20- 
03-A) and University of Milan after approval by 
the expert committee at the Department of 
Pharmacological and Biomolecular Sciences, 
University of Milan. The animal room was main-
tained within a temperature range of 22-25°C 
and relative humidity of 50%±10%. There was a 
cycle of 12 hrs light/dark (lights on at 07:00 
AM). The animals gained free access to AIN93M 
diet and filtered drinking water. 
Study design, in vivo and ex vivo imaging
Before starting the experimental study, the 
baseline luciferase activity, was measured in all 
animals by in vivo imaging and the mice were 
allocated to different experimental groups so 
that the average background luciferase activity 
at the start was comparable in all groups. In 
each experimental group, mice were matched 
for weight and background luciferase. Two dif-
ferent experimental groups (10 animals/group) 
were assigned: group 1 - vehicle (olive oil) treat-
ed group and group 2 - DMBA treated group (1 
mg/mice/once a week for 4 weeks by gavage). 
Mice were maintained in the experiment for up 
to 24 weeks (32 weeks p.b.). Details of the 
treatment protocol can be found in Figure 1. 
BLI sessions were carried out as described 
before [17] at 0, 6 hrs and 8, 13, 18, 23, 24, 
25, 26, 27 weeks p.b. at 10:00 a.m. 80 mg/Kg 
luciferin (beetle luciferin potassium salt; 
Promega, Madison, Wisconsin) was adminis-
tered i.p. to the mice and let to distribute for 15 
min before the 5 min acquisition with the CCD-
camera. For quantification, photon emission 
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was measured in the regions of interest and the 
signals obtained were integrated from each 
anatomical area as previously described [17]. 
Photon emission is defined in this work as the 
number of counts per second per square centi-
meter (cts/cm2s). Quantifications were done 
using WinLight32 imaging software (Berthold 
Technologies). Normalization was performed 
using an external source of photons enabling to 
measure the instrumental efficiency of photon 
counting (Glowell, Luxbiotech, Edinburgh, UK). 
At the last day of the experiment, after the in 
vivo imaging procedure, the animals were sacri-
hematoxylin and eosin (HE) for standard histo-
pathologic examination.
Real-time PCR for the quantification of the lev-
els of ERα mRNA transcript
Real-time PCR experiments were done with 
total RNAs extracted after tissue homogeniza-
tion in TRIzol reagent (Invitrogen, Carlsbad, CA) 
as suggested by the manufacturer’s instruc-
tions. For the preparation of cDNA, 1 µg of RNA 
was denatured at 75°C for 5 min in the pres-
ence of 1.5 µg of random primers (Promega) in 
Figure 1. Scheme of the DMBA treatment applied to the ERE-Luc reporter 
mouse. For the DMBA-induced carcinogenesis, 1 mg of the genotoxic com-
pound or its vehicle was administered by gavage to female ERE-Luc mice 
weekly for four treatments starting at 8 weeks p.b.; in agreement with the 
previously published protocol [16], the treatment was suspended for one 
week to let mice recovering without affecting the overall efficacy in the gen-
eration of breast tumors. 
Figure 2. Acute effects of DMBA treatments on ER activation. A. Five female 
ERE-Luc mice were treated by gavage with 1 mg DMBA or olive oil (vehicle) 
as described in the scheme of Figure 1: BLI acquisitions were carried out be-
fore and 6 hrs after treatment. Picture of a representative animal per group 
is shown; photon emission appears to increase in the whole abdominal area 
in the group of DMBA treated mice. B. Graphs show the quantitative mea-
surement of the photon emission from chest and abdomen. Values are ex-
pressed as counts per unit of time and area (cts/cm2s), bars are the means 
+/- SEM; Student’s t test was applied to calculate statistical significance * 
for p<0.05 and *** for p<0.001 DMBA 6 hrs versus control 6 hrs. 
ficed, selected organs were 
excised and placed in a light-
tight chamber for the ex vivo 
measurement of tissue spe-
cific signals. Gray-scale imag-
es were first taken with 
dimmed light and then photon 
emission was registered for 5 
min. Merging the signal with 
the dimmed light pictures 
enabled to visualize the tissue 
specific localization of the 
photon emission signal in 
individual organs (luciferase 
signal was transformed in 
pseudocolors: blue-low, white- 
high). 
After sacrifice, dissected org- 
ans were snap frozen in liquid 
nitrogen for the quantitative 
analysis of luciferase content 
in the tissues. Quantitative 
enzymatic luciferase assay on 
protein extract from the tis-
sues was carried out as previ-
ously described [14].
DMBA treatment
100 ul of olive oil or 1 mg of 
DMBA in 100 ul of olive oil, 
was administered to the ani-
mals by gavage. 
Histochemical analysis
Tissues were fixed in 10% neu-
tral buffered formalin (NBF), 
routinely processed and em- 
bedded in paraffin blocks. 
Breast tissues were sectioned 
at 4 μm, and stained with 
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a 15 µl final volume. Deoxynucleotide triphos-
phate (GE Healthcare) and Moloney murine leu-
kemia virus reverse transcriptase (RT; Promega) 
were added at 0.5 mM and 8 U/µl final concen-
tration, respectively, in a final volume of 25 µl. 
The RT reaction was performed at 37°C for 1 h; 
the enzyme was inactivated at 75°C for 5 min. 
Control reactions without addition of the RT 
enzyme were performed for each sample. 
Templates were amplified using the TAQMAN 
Universal PCR amplification kit (Applied 
Biosystems) in a thermocycler (ABI Prism 7000, 
Applied Biosystems). TaqMan Gene Expression 
Assays was used for ERα (Mm00433149_m1); 
for 36B4 the following primers and probe were 
used: forward 5’-ggcgacctggaagtccaact-3’, re- 
verse 5’-ccatcagcaccacagccttc-3’, probe 5’- 
atctgctgcatctgcttggagccca-3’; for ERβ the fol-
Figure 3. Chronic effects of DMBA treatments on the systemic ER activation. Five female ERE-Luc mice were treated 
as described in the scheme of Figure 1; BLI was carried out at the indicated times. Pictures of one representative 
animal of the DMBA and vehicle groups are shown in (A) or in (B), respectively. Inserted graphs represent the photon 
emissions (cts/cm2s) from the abdominal area of the corresponding individual showed in the picture. 
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lowing primers were used forward 5’-aagctggct-
gacaaggaactg-3’, reverse 5’-caggctgagctcca-
caaagc-3’. The reaction was carried out accord-
ing to the manufacturer’s protocol using Applied 
Biosystems 7000 Sequence Detection System 
device with the following thermal profile: 2 min 
at 50°C, 10 min 95°C, 40 cycles (15 s at 95°C, 
1 min at 60°C), and data were analyzed using 
the ABI Prism 7000 SDS Software and the 2-ΔΔCt 
method. The level of ERα and ERβ mRNA tran-
scripts were normalized on the constitutively 
expressed gene 36B4. 
Statistical analysis
Statistical analysis was carried out using 
GraphPad Prism 5 (GraphPad Software); we 
have applied Student’s t test analysis for deter-
mining statistical significance unless otherwise 
specified. 
Results
To gain novel insights into the dynamics of ER 
signaling during mammary carcinogenesis, we 
treated n. 5 females, 8-week old ERE-Luc 
reporter mice [14] with DMBA according to a 
previously published protocol [16]: 1 mg DMBA 
or vehicle (as negative control) was adminis-
tered by gavage weekly for four weeks with one 
week interruption between the second and the 
third week (Figure 1). The DMBA treatment was 
expected to induce adenocarcinoma in about 
60% of mice with an average latency of 31 
weeks [16]. Shortly after treatment (6 hours) or 
in the following weeks, we have studied the 
Figure 4. Identification of the source of photon emission by ex vivo imaging. (A) Magnification of the picture of the 
DMBA-treated mouse at week 23 showed in Figure 3; the photons emitted from the areas surrounding the thymus 
(orange area) and the lymph nodes (red area) are highlighted. (B) Pictures show the bioluminescence from the area 
surrounding the mammary gland, which developed a tumor (red circle); the inserted graph reports the photons emit-
ted from the tumor (cts/cm2s) in time. (C) Fold induction of the photon emission detected at week 23 p.b. versus 
week 18 p.b. in the abdominal area; for each individual, the values detected at week 23 p.b. were normalized over 
the value detected at week 18 p.b.; bars are the average calculated values (D). Ex vivo imaging analysis of photon 
emission from the tumor, abdominal mammary glands and thymus excised from the DMBA-treated mouse reported 
in (A).
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DMBA effects on ER activity by measuring pho-
ton emission [15]. In order to minimize the 
dietary effects shown to influence ER activity 
[18], animals were fasted the night before each 
BLI session. 
To evaluate the short-term effects, BLI was car-
ried out immediately before and 6 hrs after 
DMBA treatment. Photon emission was detect-
ed for 5 min upon injecting the mice with 80 
mg/Kg luciferin. After DMBA administration, 
bioluminescence increased significantly (more 
than 2-fold) in the chest and abdominal areas 
as compared to their baseline or to the biolumi-
nescence measured in vehicle-treated mice 
(Figure 2), suggesting that this genotoxic agent 
given systemically produces an initial, general-
ized activation of the receptor in several tis-
sues. This early ER activation returned to base-
line one week after the last DMBA treatment 
(compare Figure 2 after DMBA treatment with 
Figure 3 week 13 p.b.). ER signaling was near 
baseline at week 13 p.b. and at week 18 p.b. 
time points; at week 23 p.b., we registered an 
increased bioluminescence emission (Figure 
3). The average increase of bioluminescence 
observed in four (out of five) animals was about 
3). Ex vivo imaging analysis, demonstrated that 
the tumor was indeed emitting photons (Figure 
4D), while two spots of ER activation were 
detected in the abdominal mammary glands 
possibly associated to lymph nodes or to sites 
of tissue transformation (left and right). The 
thymus displayed high luciferase activity con-
firming that the signals detected on the throat/
thoracic area originated from this organ 
(Figures 3 and 4D). Similar, although not identi-
cal, dynamics of bioluminescence emission 
could be detected in different DMBA-treated 
animals, which lately developed a tumor (4 out 
of 5 animals in this experiment), and the inten-
sity of the signal was also slightly different in 
different individuals. The possibility offered by 
in vivo imaging allowed us to highlight longitudi-
nally the increase in the bioluminescence emis-
sion in each animal overcaming the intra-indi-
vidual variability which would have flattened 
the results, if a classical post-mortem group 
analysis had been carried out. Control mice 
were not showing the pattern of activation reg-
istered in the DMBA-treated animals (Figure 3); 
fluctuations in bioluminescence in this group of 
animals were most likely associated to the dif-
ferent phase of the estrus cycle [15].
Figure 5. Photon emission and luciferase activity measured from the mam-
mary glands with or without neoplastic lesions. Mammary glands with or 
without lesions were excised from the DMBA-treated animals and subject-
ed to the ex vivo imaging protocol: photon counts (cts/cm2s) were plotted 
in the graph (A). (B) Luciferase activity was measured in the protein ex-
tracts of the same mammary gland reported in (A). Data represents mean 
+/-SEM (n = 5); asterisks indicate a significant difference from control 
(vehicle), as assessed by one-way ANOVA plus Bonferroni post hoc test 
(*p<0.05) (**p<0.01) and dollar indicates a significant difference from 
control, as assessed by unpaired Student’s t-test two tailed ($p<0.05).
2.5 fold the level of light emis-
sion detected at week 18 p.b. 
(Figure 4C). The increased ER 
activation was not restricted 
to the mammary glands but 
spread in the area correspond-
ing to lymph nodes and thymus 
(Figure 4A). From this time point 
(23 p.b.), we proceeded with a 
weekly BLI acquisition of the 
mouse bioluminescence (Figure 
3). At week 24 p.b. biolumines-
cence increased in the abdomi-
nal area and a novel circular 
signal was detectable in proxim-
ity of the left anterior leg 
(Figures 3 and 4B). The abdomi-
nal signal further increased at 
week 25 p.b. extending to the 
liver corresponding area, and a 
tumor became palpable in cor-
respondence of the left anterior 
leg (Figure 3). While the abdom-
inal signal decreased during 
the following weeks, the tumor-
associated signal increased 
until week 27 p.b., when the 
mouse was euthanized (Figure 
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To demonstrate that ER signaling was indeed 
ectopically activated in the transformed tis-
sues, both tumor and morphologically untrans-
formed mammary glands were collected at 
week 27 p.b. for ex vivo imaging and luciferase 
enzymatic assay. Most of the tumors had high-
er bioluminescent signal and expressed signifi-
cantly higher luciferase activity compared to 
the mammary glands without morphological 
signs of transformation (Figure 5); this indicat-
ed that most of the DMBA-induced tumors were 
ER positives as also previously reported [19]. 
Finally, we tested whether the methodology 
was able to identify sites of incipient transfor-
mation prior detection of a palpable tumor. 
Thus, in a duplicate experiment, mice from con-
trol and DMBA-treated groups (with no palpable 
tumors) were sacrificed at week 21 p.b. and 
subjected to in vivo and ex vivo imaging (Figure 
6). Ex vivo imaging showed specific spots of bio-
luminescence in the mammary glands of the 
DMBA-treated group not observed in the vehi-
cle treated animals. These spots were inter-
preted as possible sites of incipient transfor-
mation (see red arrows in Figure 6B); indeed, 
immunohistochemistry revealed the presence 
of in situ hyperproliferation (Figure 7A), which is 
usually preceding the appearance of a primary 
cancer; the hyperproliferation was not present 
in the mammary gland of vehicle-treated mice. 
Interestingly, the ERα mRNA content in hyper-
plastic tissue was comparable to controls and 
we recorded only a non significant, increase of 
the ERβ mRNA in the hyperplastic tissue (Figure 
7B); this is suggesting that the increased biolu-
minescence observed in the hyperplasia was 
only partially due to the increased receptor 
expression, other mechanisms might also be 
involved, like for example activation of the ER 
Figure 6. In vivo and ex vivo imaging analysis of the breast tissue from DMBA-treated mice before tumor appear-
ance. Pictures in the left show in vivo imaging analysis of a representative individual of the group of mice treated 
with vehicle (A) or DMBA (B). Pictures on the right show the photon emission coming from mammary glands, lymph 
nodes, thymus and spleen explanted from the same mice after sacrifice. An increased photon emission was vis-
ible in thymus and in selected spots of the mammary glands form the DMBA-treated mice compared to the control 
mammary glands.
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signaling by local hormone production (ligand-
ed activation) or by the cross-talk with other 
membrane receptor signaling pathways (unli-
ganded activation) [5]. 
Taken together, our data indicate that imaging 
luciferase activity in the ERE-Luc reporter 
mouse may allow a dynamic analysis of recep-
tor activation during breast cancer progression; 
the possibility, during breast carcinogenesis, to 
localize the activation of ER signaling in the 
spatial (position in the body and within the tis-
sue) and temporal dimensions may direct the 
genomic analysis to the precise site in the 
breast where neoplastic transformation is 
occurring, before a palpable tumor become 
detectable.
Discussion
In this study we aimed at demonstrating the 
applicability of BLI to the study of ER signaling 
during breast transformation. The choice to 
apply the DMBA protocol to induce mammary 
tumors was dictated by the possibility to gener-
ate sporadic, hormone-dependent cancers [19] 
which closely resemble the human breast 
tumors [16]. Tumors were induced in the ERE-
Luc reporter mouse; in this model, several 
pharmacological, molecular and physiological 
studies carried out in our and other laborato-
ries firmly demonstrated the direct relation 
between luciferase expression and ER activa-
tion in response to physiological [15], pharma-
cological [20] and dietary estrogens [18]. In the 
current study, we believe to have demonstrated 
that the methodology we have developed is 
suitable for measuring ER signaling during 
breast transformation in the same animal over 
time during the progression of the DMBA-
induced mammary lesions. This might finally 
lead to identify from the molecular stand-point 
where ER is transcriptionally active; this precise 
spatio-temporal localization would enable to 
identify novel targets for anti-cancer agents. 
Another added value of this methodology is the 
possibility to carry out a systemic whole body 
analysis of ER activation, allowing to highlight 
other tissues potentially relevant for breast 
cancer progression (e.g. lymph nodes and 
thymus). 
Furthermore, in our report we show that the 
pattern of ER activation seems to “label” a 
Figure 7. Histochemical analysis of the breast tissues form DMBA- and vehicle-treated mice at 21 weeks of age. A. 
Eosin/hematoxylin staining shows the presence of in situ hyperproliferative foci in the mammary gland of the mice 
treated with DMBA at this stage of tumorigenesis. B. Real time PCR analysis of ERα and ERβ expression in normal 
and hyperplastic mammary glands at 21 weeks of age. Bars represent the levels of ERα and ERβ mRNAs normalized 
on the reference gene 36B4 calculated using the 2-ΔΔCt method.
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phase which is prodromal to the tumor appear-
ance; this phase is characterized by a 2.5 fold 
increase of bioluminescence (Figure 4C), a 
threshold increase which can be used in future 
studies aimed at defining novel steps in which 
ER signaling might play a role that were not 
identified by the current analysis (for example 
in earlier time points between 13 p.b. and 23 
p.b). Once identified a step characterized by an 
increased ER activation, further molecular 
studies (i.e. transcriptomic, proteomic or 
metabolomic studies) can be driven by the ex 
vivo imaging analysis on the portion of the 
mammary gland interested by the transforma-
tion event (Figure 6). 
One limitation of the DMBA-based protocol 
applied in the current study is that it generates 
only primary, locally invasive, non metastatic 
tumors limiting the analysis to the early steps of 
mammary transformation. Future studies might 
consider to overcome this limitation, by breed-
ing the ERE-Luc model with GEM which are spe-
cifically developing metastatic cancer (e.g. 
MMTVneu) [21]. In models of this type, there 
will be the possibility to investigate specific 
aspects of ER activation in the process of 
metastasis, which cannot be easily addressed 
using classical models. For example, we have 
demonstrate the possibility to study ER activity 
in the immune system (i.e. see lymph nodes, 
spleen, thymus Figure 4); in a metastatic 
model, it will be possible to address specific 
questions regarding the functional role of the 
receptor signaling in inflammatory cells during 
the process of metastasis [22]. 
Conclusions
In conclusion, to our knowledge this is the first 
report demonstrating ER signal during the 
entire carcinogenesis process in the same indi-
vidual: this demonstration might open the pos-
sibility to elucidate in the spatio/temporal 
dimension the molecular changes occurring 
upon ER activation during the process of neo-
plastic transformation.
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